Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Lasser

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
European Psychiatry : the Journal of the Association of European Psychiatrists|June 16, 2004
Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidoneRobert A Lasser, Cynthia A Bossie, Georges M Gharabawi, et al.
The Journal of the Louisiana State Medical Society : Official Organ of the Louisiana State Medical Society|October 24, 1998
Intraplaque verapamil injection for treatment of Peyronie's diseaseA Lasser, T L Vandenberg, M J Vincent, et al.
The International Journal of Neuropsychopharmacology|April 5, 2005
Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trialRobert A Lasser, Cynthia A Bossie, Georges M Gharabawi, et al.
Psychiatry (Edgmont (Pa. : Township))|September 3, 2009
A New Psychosocial Tool for Gaining Patient Understanding and Acceptance of Long-acting Injectable Antipsychotic TherapyRobert A Lasser, Nina R Schooler, Mary Kujawa, et al.
Community Mental Health Journal|March 9, 2007
Evaluation of a treatment manual for risperidone long-acting injectableJohn P Docherty, Robert Jones, Ibrahim Turkoz, et al.
Schizophrenia Research|May 24, 2005
Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injectionRobert A Lasser, Cynthia A Bossie, Georges M Gharabawi, et al.
Schizophrenia Research|November 25, 2004
Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophreniaJohn Lauriello, Joseph P McEvoy, Stephen Rodriguez, et al.
Nature Reviews. Clinical Oncology|January 9, 2024
Myeloid-derived suppressor cells in cancer and cancer therapySamantha A Lasser, Feyza G Ozbay Kurt, Ihor Arkhypov, et al.
International Clinical Psychopharmacology|May 12, 2006
Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidoneGeorges M Gharabawi, Robert A Lasser, Cynthia A Bossie, et al.
Schizophrenia Research|May 26, 2005
An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term studyGeorges M Gharabawi, Cynthia A Bossie, Young Zhu, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
European Psychiatry : the Journal of the Association of European Psychiatrists|June 16, 2004
Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidoneRobert A Lasser, Cynthia A Bossie, Georges M Gharabawi, et al.
The Journal of the Louisiana State Medical Society : Official Organ of the Louisiana State Medical Society|October 24, 1998
Intraplaque verapamil injection for treatment of Peyronie's diseaseA Lasser, T L Vandenberg, M J Vincent, et al.
The International Journal of Neuropsychopharmacology|April 5, 2005
Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trialRobert A Lasser, Cynthia A Bossie, Georges M Gharabawi, et al.
Psychiatry (Edgmont (Pa. : Township))|September 3, 2009
A New Psychosocial Tool for Gaining Patient Understanding and Acceptance of Long-acting Injectable Antipsychotic TherapyRobert A Lasser, Nina R Schooler, Mary Kujawa, et al.
Community Mental Health Journal|March 9, 2007
Evaluation of a treatment manual for risperidone long-acting injectableJohn P Docherty, Robert Jones, Ibrahim Turkoz, et al.
Schizophrenia Research|May 24, 2005
Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injectionRobert A Lasser, Cynthia A Bossie, Georges M Gharabawi, et al.
Schizophrenia Research|November 25, 2004
Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophreniaJohn Lauriello, Joseph P McEvoy, Stephen Rodriguez, et al.
Nature Reviews. Clinical Oncology|January 9, 2024
Myeloid-derived suppressor cells in cancer and cancer therapySamantha A Lasser, Feyza G Ozbay Kurt, Ihor Arkhypov, et al.
International Clinical Psychopharmacology|May 12, 2006
Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidoneGeorges M Gharabawi, Robert A Lasser, Cynthia A Bossie, et al.
Schizophrenia Research|May 26, 2005
An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term studyGeorges M Gharabawi, Cynthia A Bossie, Young Zhu, et al.
Pageof 7